Literature DB >> 30414523

Serum Biomarkers and Clinical Outcomes in Traumatic Spinal Cord Injury: Prospective Cohort Study.

Marcelo de Mello Rieder1, Jean Pierre Oses2, Fernanda Machado Kutchak1, Mônia Sartor3, André Cecchini4, Marcelo Salimen Rodolphi3, Carolina David Wiener2, Afonso Kopczynski3, Alexandre Pastoris Muller5, Nathan Ryzewski Strogulski3, Randhall B Carteri3, Gisele Hansel6, Marino Muxfeldt Bianchin7, Luis Valmor Portela8.   

Abstract

BACKGROUND: A plethora of reactive cellular responses emerge immediately after a traumatic spinal cord injury (SCI) and may influence the patient's outcomes. We investigated whether serum concentrations of neuron-specific enolase, interleukin-6, glial-derived neurotrophic factor, and neurotrophic growth factor reflect the acute-phase responses to different etiologies of SCI and may serve as predictive biomarkers of neurologic and functional outcomes.
METHODS: Fifty-two patients were admitted to the intensive care unit after SCI due to traffic accidents, falls, and firearm wounds and had blood samples collected within 48 hours and 7 days after SCI. Thirty-six healthy subjects with no history of SCI were included as controls. Neurologic and functional status was evaluated on the basis of American Spinal Injury Association and Functional Independence Measure scores over a period of 48 hours and 6 months after SCI.
RESULTS: Serum NSE increased significantly 48 hours and 7 days after SCI compared with controls, while interleukin-6 increased only at 48 hours. In contrast, the neurotrophic growth factor level significantly decreased 48 hours and 7 days after SCI. Serum glial-derived neurotrophic factor level did not differ from control at any time point. Also, there was no significant difference in biomarker concentrations between the etiologies of SCI or the level of spinal injury. There were no correlations between biomarker levels at 48 hours with neurologic or functional outcomes 7 days and 6 months after SCI.
CONCLUSIONS: Our results suggest expansive axonal damage coupled with an acute proinflammatory response after SCI. However, in our study biomarker concentration did not correlate with short- or long-term prognosis, such as survival rate or sensory and motor function.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GDNF; IL-6; NGF; NSE; Serum biomarkers; Spinal cord injury

Mesh:

Substances:

Year:  2018        PMID: 30414523     DOI: 10.1016/j.wneu.2018.10.206

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  3 in total

1.  Trends in Rates of ASIA Impairment Scale Conversion in Traumatic Complete Spinal Cord Injury.

Authors:  Ralph J Marino; Michael Leff; Diana D Cardenas; Jayne Donovan; David Chen; Steve Kirshblum; Benjamin E Leiby
Journal:  Neurotrauma Rep       Date:  2020-11-13

Review 2.  Improving Diagnostic Workup Following Traumatic Spinal Cord Injury: Advances in Biomarkers.

Authors:  Simon Schading; Tim M Emmenegger; Patrick Freund
Journal:  Curr Neurol Neurosci Rep       Date:  2021-07-16       Impact factor: 5.081

3.  Blood Serum Cytokines in Patients with Subacute Spinal Cord Injury: A Pilot Study to Search for Biomarkers of Injury Severity.

Authors:  Sergei Ogurcov; Iliya Shulman; Ekaterina Garanina; Davran Sabirov; Irina Baichurina; Maxim Kuznetcov; Galina Masgutova; Alexander Kostennikov; Albert Rizvanov; Victoria James; Yana Mukhamedshina
Journal:  Brain Sci       Date:  2021-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.